RecruitingAcute Myeloid LeukemiaAcute Lymphoblastic T-cell LeukemiaMixed Phenotype Acute Leukemia
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
Eligible age
0.1–25 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic stem cell transplantation in a cohort of pediatric and young adult patients with chemorefractory or minimal residual disease (MRD) positive acute leukemia.
Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology
You may qualify if…
- ✓ 1. Patient (age from 14 to 25 years) and/or patient's legal representative (age from 0 to 18 years) should provide written informed consent.
- ✓ 2. Patients with one of the following disease:
- ✓ Acute myeloid leukemia: a. primary refractory disease (absence of complete remission (CR) after two induction regimens), b. refractory relapse (absence of CR after one salvage regimen), c. MRD-persistence before conditioning (presence of residual leukemic population more than 0,01% of bone marrow nucleated cells by flow cytometry);
- ✓ Acute T-lymphoblastic leukemia: a. primary refractory disease (absence of complete remission (CR) after two induction regimens), b. refractory relapse (absence of CR after one salvage regimen), c. MRD-persistence before conditioning (presence of residual leukemic population more than 0,1% of bone marrow nucleated cells by flow cytometry);
- ✓ Acute mixed phenotype leukemia: a. primary refractory disease (absence of complete remission (CR) after two induction regimens), b. refractory relapse (absence of CR after one salvage regimen), c. MRD-persistence before conditioning (presence of residual leukemic population more than 0,01% of bone marrow nucleated cells by flow cytometry).
- ✓ 3. Patient is indicated to receive allo-HSCT according to actual clinical practice.
- ✓ 4. Haploidentical or matched related donor was chosen and is available for allo-HSCT (and NK-cell therapy).
- ✓ 5. Patient's clinical status: Lansky/Karnowski index ≥50%.
You may not qualify if…
- ✕ 1. Inability to provide or withdrawal of written informed consent.
- ✕ 2. Cellular therapy including allo-HSCT within prior 4 months period, absence of active signs of GVHD, sinusoidal obstruction syndrome, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome.
- ✕ 3. Active hepatitis B, C or HIV infection.
- ✕ 4. Pregnant or lactating women.
- ✕ 5. Uncontrolled infection; principal investigator is the final arbiter of this criterion.
- ✕ 6. Clinical signs of grade ≥3 CNS disorders (seizure disorder, paresis, aphasia, cerebrovascular ischemia/hemorrhage, severe brain injuries, dementia, organic brain syndrome, psychosis, coordination or movement disorder).
- ✕ 7. Mental illness of the patient or caregivers, making it impossible to realize the essence of the study and compromising compliance with medical appointments and sanitary and hygienic regime.
Source: ClinicalTrials.gov · NCT07256210 · last updated 2025-12-01